1-9 of 9
Seda S. Tolu
Close
Sort by
Journal Articles

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

Seda S. Tolu, Alexander Sanjurjo, David Destephano, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4431.
https://doi.org/10.1182/blood-2023-177722
Published: 2023
Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4391.
https://doi.org/10.1182/blood-2023-179271
Published: 2023
Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 6118.
https://doi.org/10.1182/blood-2023-180875
Published: 2023
Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan
Journal: Blood
Blood (2023) 142 (Supplement 1): 1698.
https://doi.org/10.1182/blood-2023-178231
Published: 2023
Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2023-186639
Published: 2023
Journal Articles

Queen's gambit: response-adapted win in CAYA with cHL

Clinical Trials & Observations
Seda S. Tolu, Jennifer E. Amengual
Journal: Blood
Blood (2023) 141 (17): 2037–2038.
https://doi.org/10.1182/blood.2022019339
Published: 2023
Journal Articles

High Hemoglobin F in Sickle Cell Disease: Waning Protection with Age

Seda S. Tolu, MD, Morayma Reyes Gil, MD PhD, Ugochi Olivia Ogu, MD, Jui Choudhuri, MD, Roger Fecher, MD, Gracy Sebastian, NP, Caterina P. Minniti, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3576.
https://doi.org/10.1182/blood-2019-122387
Published: 2019
Journal Articles

Common Myeloid Progenitors As Biomarkers of Hbf Response to Hydroxyurea in Sickle Cell Disease

Caterina P. Minniti, MD, Seda S. Tolu, MD, Kai Wang, PhD, Zi Yan, Andrew Crouch, Gracy Sebastian, NP, Mark Chaitowitz, MD, Evan Schwechter, MD, Joan Uehlinger, MD, Deepa Manwani, MD, Eric Fornari, MD, Eric E. Bouhassira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4827.
https://doi.org/10.1182/blood-2019-131466
Published: 2019
Journal Articles

Long-Term Hydroxyurea Use Is Associated with Lower Levels of Hematopoietic Stem and Progenitor Cells in Patients with Sickle Cell Disease

Seda S. Tolu, MD, Kai Wang, PhD, Zi Yan, Andrew Crouch, Gracy Sebastian, NP, Mark Chaitowitz, MD, Eric Fornari, MD, Evan Schwechter, MD, Joan Uehlinger, MD, Deepa Manwani, MD, Caterina P. Minniti, MD, Eric E. Bouhassira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 985.
https://doi.org/10.1182/blood-2019-131648
Published: 2019